



ISPRO

Istituto per lo studio, la prevenzione
e la rete oncologica



Implementation of regional HPV-based screening; Challenges and way forward to national implementation. The Italian policy.


Francesca Maria Carozzi
Responsible
Responsible for hpv implementation in Tuscany Region
Director Regional Laboratory For Cancer Prevention
ISPRO- Florence -Italy

Contents

- Background: Cervical Cancer screening in Italy
- The HPV- primary test strategy in Italy: protocol, age, interval.
- Where we are today
- Data from 2° round of HPV screening
- The LABs in the regional programs and LABs quality control.
- COVID19 and HPV-primary testing.

Cervical Cancer Screening: target Age 25-64 y

Different protocols by age




HPV Screening In Italy : 19 regions out of 21



Different models of lab centralisation by region

All screening programs use HPV validated test

	Regioni
2012	10
2013	10
2014	12
2015	12
2016	15
2017	16
2018	17
2019	19



Documents for HPV screening Implementacion



**External Quality
assurance programs
for HPV and cytology
triage**


HPV test EQA

Pap Triage EQA




- List of HPV test Validated for Cervical Cancer Screening according to the European Guidelines Test HPV
- ONS-GISCiReport N°. 4 31 January 2019
- Document is updated annually and available on the web site www.gisci.it



Women invited to HPV screening from 2015 to 2018



Compliance to screenig invitation by year and MACROAREA




Protocol HPV Cervical Cancer Screening




HPV Screening In Italy : 19 regions out of 21

Different models of lab centralisation by region

All screening programs are using HPV validated test



DATI SURVEY HPV 2018 REGIONE TOSCANA Positività Test HPV Primario






Standard ONS-Gisci
HPV 5-9%

Survey Italia* 2017: 5,4%-13,1%

Survey Toscana 2018: 5,7%-12,6%

% HPV inadeguati RT
Italia

0,02%
0.14



Screening Protocol in Vaccinated women

‘Consensus Study’ :

Preliminary Results in Florence Area

HPV primary test (Cobas4800) – **partial** genotyping

	Enrolled women	HR-HPV n	HR-HPV %
Vaccinated	1,605	281	17.5
Unvaccinated	457	121	26.5
Total	2,062	402	19.5

p value < 0.01

La positività del test HPV fra le donne vaccinate è circa 32% inferiore rispetto a quella delle donne non vaccinate (17,9% vs. 26,4%; $p < 0,01$)

Cervical Screening in Italy e Lockdown SARS-COV-2

- **Stop of screening programas 15 march 2020 at national level**
- **In 2020 , the screening tests are about 55,3% less than in 2019**
There are small fluctuations between the Regions, however no Region at the end of May 2020 has accumulated delays of less than 40%.
- **This value transformed into time becomes an average delay of 2.8 standard months (with fluctuations ranging from 2.1 to 3.2 standard months).**
- **The number of undiagnosed CIN 2 or more severe injuries is estimated at 1,676**
- **Fortunately, at the moment the accumulated mean diagnostic delay is quite limited and the clinical consequences are probably not particularly pronounced**
- **The screening is now re-opened (from 15 may 2020) but the compliance is lower than expected and from september we re-start with usual overbooking (4 women every 15 min)**
- **Self-sampling option is under evaluation not only for not-responder but expecially for women in HPV program at 2° round of screening**

Thanks for your attention
f.carozzi@ispro.toscana.it

